FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308721981> ?p ?o ?g. }

• W4308721981 abstract "Background: Despite (neo) adjuvant chemotherapy with cisplatin, doxorubicin and methotrexate, some patients with primary osteosarcoma progress during first-line systemic treatment and have a poor prognosis. In this study, we investigated whether patients with early disease progression (EDP), are characterized by a distinctive pharmacogenetic profile. Methods and Findings: Germline DNA from 287 Dutch high-grade osteosarcoma patients was genotyped using the DMET Plus array (containing 1,936 genetic markers in 231 drug metabolism and transporter genes). Associations between genetic variants and EDP were assessed using logistic regression models and associated variants ( p &lt;0.05) were validated in independent cohorts of 146 (Spain and United Kingdom) and 28 patients (Australia). In the association analyses, EDP was significantly associated with an SLC7A8 locus and was independently validated (meta-analysis validation cohorts: OR 0.19 [0.06–0.55], p = 0.002). The functional relevance of the top hits was explored by immunohistochemistry staining and an in vitro transport models. SLC7A8 encodes for the L-type amino acid transporter 2 (LAT2). Transport assays in HEK293 cells overexpressing LAT2 showed that doxorubicin, but not cisplatin and methotrexate, is a substrate for LAT2 ( p &lt; 0.0001). Finally, SLC7A8 mRNA expression analysis and LAT2 immunohistochemistry of osteosarcoma tissue showed that the lack of LAT2 expression is a prognostic factor of poor prognosis and reduced overall survival in patients without metastases ( p = 0.0099 and p = 0.14, resp.). Conclusion: This study identified a novel locus in SLC7A8 to be associated with EDP in osteosarcoma. Functional studies indicate LAT2-mediates uptake of doxorubicin, which could give new opportunities to personalize treatment of osteosarcoma patients." @default.
• W4308721981 created "2022-11-15" @default.
• W4308721981 creator A5000183191 @default.
• W4308721981 creator A5004194069 @default.
• W4308721981 creator A5005290498 @default.
• W4308721981 creator A5014696224 @default.
• W4308721981 creator A5017137776 @default.
• W4308721981 creator A5018163150 @default.
• W4308721981 creator A5018890674 @default.
• W4308721981 creator A5018959951 @default.
• W4308721981 creator A5024830756 @default.
• W4308721981 creator A5025421171 @default.
• W4308721981 creator A5027904678 @default.
• W4308721981 creator A5030485933 @default.
• W4308721981 creator A5037151292 @default.
• W4308721981 creator A5039310063 @default.
• W4308721981 creator A5040793363 @default.
• W4308721981 creator A5041163951 @default.
• W4308721981 creator A5046390152 @default.
• W4308721981 creator A5054734188 @default.
• W4308721981 creator A5055163903 @default.
• W4308721981 creator A5057092406 @default.
• W4308721981 creator A5064375626 @default.
• W4308721981 creator A5064691832 @default.
• W4308721981 creator A5065228177 @default.
• W4308721981 creator A5067758329 @default.
• W4308721981 creator A5069175196 @default.
• W4308721981 creator A5069495532 @default.
• W4308721981 creator A5070010039 @default.
• W4308721981 creator A5076321542 @default.
• W4308721981 creator A5082316302 @default.
• W4308721981 creator A5089588265 @default.
• W4308721981 date "2022-11-09" @default.
• W4308721981 modified "2023-10-18" @default.
• W4308721981 title "SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin" @default.
• W4308721981 cites W1491334685 @default.
• W4308721981 cites W1580800547 @default.
• W4308721981 cites W1975253840 @default.
• W4308721981 cites W2017611639 @default.
• W4308721981 cites W2018477183 @default.
• W4308721981 cites W2019688507 @default.
• W4308721981 cites W2041323112 @default.
• W4308721981 cites W2071041228 @default.
• W4308721981 cites W2073733308 @default.
• W4308721981 cites W2073867312 @default.
• W4308721981 cites W2084214117 @default.
• W4308721981 cites W2085643392 @default.
• W4308721981 cites W2088750699 @default.
• W4308721981 cites W2088839227 @default.
• W4308721981 cites W2093500966 @default.
• W4308721981 cites W2096515859 @default.
• W4308721981 cites W2096748119 @default.
• W4308721981 cites W2097904291 @default.
• W4308721981 cites W2118783447 @default.
• W4308721981 cites W2127859885 @default.
• W4308721981 cites W2128486176 @default.
• W4308721981 cites W2129566658 @default.
• W4308721981 cites W2134929696 @default.
• W4308721981 cites W2139974473 @default.
• W4308721981 cites W2142896730 @default.
• W4308721981 cites W2147327697 @default.
• W4308721981 cites W2149700196 @default.
• W4308721981 cites W2155036184 @default.
• W4308721981 cites W2161633633 @default.
• W4308721981 cites W2163261709 @default.
• W4308721981 cites W2166376857 @default.
• W4308721981 cites W2182249053 @default.
• W4308721981 cites W2207814108 @default.
• W4308721981 cites W2395401987 @default.
• W4308721981 cites W2397338589 @default.
• W4308721981 cites W2401384141 @default.
• W4308721981 cites W2901802145 @default.
• W4308721981 cites W2911188335 @default.
• W4308721981 cites W3012335292 @default.
• W4308721981 cites W3013381886 @default.
• W4308721981 cites W3196789286 @default.
• W4308721981 doi "https://doi.org/10.3389/fphar.2022.1042989" @default.
• W4308721981 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36438828" @default.
• W4308721981 hasPublicationYear "2022" @default.
• W4308721981 type Work @default.
• W4308721981 citedByCount "0" @default.
• W4308721981 crossrefType "journal-article" @default.
• W4308721981 hasAuthorship W4308721981A5000183191 @default.
• W4308721981 hasAuthorship W4308721981A5004194069 @default.
• W4308721981 hasAuthorship W4308721981A5005290498 @default.
• W4308721981 hasAuthorship W4308721981A5014696224 @default.
• W4308721981 hasAuthorship W4308721981A5017137776 @default.
• W4308721981 hasAuthorship W4308721981A5018163150 @default.
• W4308721981 hasAuthorship W4308721981A5018890674 @default.
• W4308721981 hasAuthorship W4308721981A5018959951 @default.
• W4308721981 hasAuthorship W4308721981A5024830756 @default.
• W4308721981 hasAuthorship W4308721981A5025421171 @default.
• W4308721981 hasAuthorship W4308721981A5027904678 @default.
• W4308721981 hasAuthorship W4308721981A5030485933 @default.
• W4308721981 hasAuthorship W4308721981A5037151292 @default.
• W4308721981 hasAuthorship W4308721981A5039310063 @default.
• W4308721981 hasAuthorship W4308721981A5040793363 @default.
• W4308721981 hasAuthorship W4308721981A5041163951 @default.
• W4308721981 hasAuthorship W4308721981A5046390152 @default.
• W4308721981 hasAuthorship W4308721981A5054734188 @default.

• next